CIDRAP newsletters options
A hypothesis that says mask wearing could reduce the infectious dose is dangerous, some experts say.
The head of the WHO warns that ongoing surges in Europe and North America mark a critical moment for action.
The findings come as a report highlights rises in US nursing home cases, especially in the Midwest.
The 7-day average of new daily SARS-CoV-2 infections is higher than 81,000.
A PLOS Medicine study late last week found double the incidence of acute kidney injury (AKI) in hospitalized COVID-19 patients and a threefold higher mortality than in COVID-19–negative patients. Men, nonwhite patients, and those with comorbidities were at increased risk of developing AKI with COVID-19.
Hospital room floors could be an underappreciated source of healthcare-associated pathogen spread, including those resistant to antibiotics, according to a study today in Infection Control and Hospital Epidemiology.
The drug reduced viral loads by a factor of 3.4 at one dosage tested.
Colorado, Illinois, and New Mexico report record daily cases, and illness levels are rising in 42 states.
Of HCWs with high-risk exposure, 7% tested positive, but 13% exposed outside the workplace tested positive.
Belgium becomes another European country to announce a national lockdown.
New data released today in Morbidity and Mortality Weekly Report (MMWR) show that household transmission of SARS-CoV-2, the virus that causes COVID-19, is common, occurs early after illness onset, and can originate from both children and adults.
Our weekly wrap-up of antimicrobial stewardship & antimicrobial resistance scans
Telemedicine visits for urinary tract infections (UTIs) were associated with more appropriate antibiotic prescribing and decreased use of diagnostic and follow-up resources than virtual visits, according to the results of a primary care network study published yesterday in Infection Control and Hospital Epidemiology.
A single student was the likely source of an outbreak that infected 76% of attendees.
In vaccine news, Moderna looks to having phase 3 trial results before December.
Yesterday the Centers for Disease Control and Prevention (CDC) reported two separate Escherichia coli O157:H7 outbreaks in the United States. Neither has an identified source, and one has already proved deadly.
A study yesterday in Science reports that the vast majority of patients with mild-to-moderate COVID-19 have stable levels of antibodies for at least 5 months.
In recent weeks Europe has become one of the world's biggest pandemic hot spots.
Many facilities have less than 1 week's supply of at least one type of protective equipment.
"Cases are actually going up. And we know that, too, because hospitalizations are going up."
